Iceland

Iceland has a restrictive controlled-drug framework for classic psychedelics, with psilocybin, MDMA, mescaline, LSD-related substances and others listed as controlled under the Narcotic Drugs Act and related schedules. In practice, psychedelic access appears limited to approved medicines and authorised research settings rather than routine clinical use.

Ask Blossom about this country

Data updated May 18, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inIceland.

1
The legal baseline is prohibition-first rather than permissive, so patient access is likely to be narrow and paperwork-heavy even where medical exceptions exist.
2
Esketamine is the only clearly supported psychedelic-derived medicine pathway visible in the sources; this should not be generalised to psilocybin, MDMA or other classic psychedelics.
3
The local ecosystem looks academically curious but small, with university and hospital authors publishing on psilocybin rather than demonstrating a mature treatment programme.
4
No source found here supports a public reimbursement route for classic psychedelics in Iceland, so any practical access would probably depend on exceptional authorisation or research participation.
5
Because Blossom's linked-trial count is zero, the most defensible framing is 'early-stage interest, no mapped domestic trial activity' rather than any implication of an active national research hub.

Research and Access Snapshot

Blossom currently tracks no country-linked psychedelic clinical trials for Iceland, but the page does include 2 stakeholders and 3 events.

Blossom has not linked country-level trial records yet. Treat this as a coverage gap, not proof that no local policy discussion, care, or informal activity exists.

Active trials: 0
Total trials: 0
Stakeholders: 2
Events: 3

Top Compounds

Linked country trials do not show a leading compound yet.

Medical Access

Iceland maintains a restrictive national narcotics law that explicitly lists many classic psychedelic compounds as controlled substances; medical access is limited to approved pharmaceutical products and authorised clinical research, while investigational or off-label psychedelic psychotherapy remains nascent and largely confined to research or private arrangements. The only psychedelic-derived product with a formal EU marketing authorisation that is relevant to Iceland is esketamine (Spravato); other compounds (psilocybin, MDMA, DMT, mescaline...

View stakeholders→View events→Open access guide→

Regulatory Status

Iceland's narcotics law and medicines oversight indicate a restrictive regime: classic psychedelics are controlled substances, and non-approved import, sale, production and distribution are prohibited unless specially licensed or authorised. The clearest legitimate access pathway for a psychedelic-derived medicine is esketamine (Spravato), which has EU/EEA authorisation and appears in the Icelandic medicines context; beyond that, psychedelic psychotherapy or off-label clinical use appears limited, and any private access claims should be treated cautiously.